SCHEMBL22200482

SCHEMBL22200482

CC(C)n1c(=O)c(-c2ccc(NS(=O)(=O)CC3(C(F)(F)F)CCC3)c(F)c2)nc2cnc(N[C@H]3CC[C@H](N(C)C)CC3)nc21

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 5/20 0.80
CCNE1 P24864 5/20 0.36
CDK2 P24941 5/20 0.36
CCNE2 O96020 2/20 0.36
MAPK8 P45983 8/20 0.36
MAPK10 P53779 7/20 0.36
MAPK9 P45984 6/20 0.36
MAPK14 Q16539 4/20 0.35
BRAF P15056 1/20 0.34
JAK2 O60674 1/20 0.34
BRD4 O60885 1/20 0.34
JAK1 P23458 1/20 0.34
BRD2 P25440 1/20 0.34
JAK3 P52333 1/20 0.34
BRD3 Q15059 1/20 0.34
BRDT Q58F21 1/20 0.34
CCND1 P24385 3/20 0.34
CDK6 Q00534 3/20 0.34
CCNT1 O60563 1/20 0.34
CDK4 P11802 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29356260 1.00 ERN1 (0.80) ERN1CCNE1CDK2CCNE2MAPK8
SCHEMBL22191200 1.00 ERN1 (0.80) ERN1CCNE1CDK2CCNE2MAPK8
SCHEMBL22200508 0.93 ERN1 (0.77) ERN1CCNE1CDK2CCNE2MAPK8
SCHEMBL29353142 0.93 ERN1 (0.77) ERN1CCNE1CDK2CCNE2MAPK8
SCHEMBL22191171 0.93 ERN1 (0.77) ERN1CCNE1CDK2CCNE2MAPK8
SCHEMBL29357838 0.89 ERN1 (0.67) ERN1CCNE1CDK2CCNE2MAPK8
SCHEMBL22200483 0.89 ERN1 (0.67) ERN1CCNE1CDK2CCNE2MAPK8
SCHEMBL22191245 0.89 ERN1 (0.67) ERN1CCNE1CDK2CCNE2MAPK8
SCHEMBL22191304 0.89 ERN1 (1.00) ERN1CCNE1CDK2CCNE2MAPK8
SCHEMBL22200499 0.89 ERN1 (1.00) ERN1CCNE1CDK2CCNE2MAPK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230047209-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE PARAZA PHARMA, INC. (CA) 2023-02-16 US disclosed
WO-2020142612-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. GENENTECH, INC. (US) 2020-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230047209-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE TYMP, TYMS, DPYD ERN1 3167/4885CCNE1 1158/4885CDK2 126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.